August 17, 2021
by Texas A&M University
Vascular diseases such as aneurysms, peripheral artery disease and clots inside blood vessels account for 31% of global deaths. Despite this clinical burden, cardiovascular drug advancements have slowed over the past 20 years. The decrease in cardiovascular therapeutic development is attributed to the lack of efficiency in converting possible treatments into approved methods, specifically due to the discrepancy between studies that take place outside the body compared to inside.
Researchers at Texas A&M University aim to remodel current methodologies to minimize this gap and improve the translatability of these techniques by directing 3D bioprinting toward vascular medicine.